$8.55
-0.01 (-0.12%)
Open$8.54
Previous Close$8.56
Day High$8.55
Day Low$8.53
52W High$10.14
52W Low$4.50
Volume—
Avg Volume92.2K
Market Cap181.85M
P/E Ratio—
EPS$-1.09
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+283.3% upside
Current
$8.55
$8.55
Target
$32.77
$32.77
$27.05
$32.77 avg
$46.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.85M | 16.36M | 16.49M |
| Net Income | -25,989,633 | -919,800 | -1,097,385 |
| Profit Margin | -202.2% | -5.6% | -6.7% |
| EBITDA | -28,466,106 | -1,433,447 | -1,263,705 |
| Free Cash Flow | — | -1,064,720 | -1,173,966 |
| Rev Growth | — | +3.8% | -10.0% |
| Debt/Equity | — | 1.22 | 1.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |